Xeltis’ restorative aortic valves at HVS
06 . 04 . 2018

Xeltis’ restorative aortic valves at HVS

Dr Gregory Fontana, National Medical Director for Cardiovascular Research, at the Hospital Corporation of America, Nashville, Tennessee, (U.S.), will present data on Xeltis’ restorative aortic valves at the Heart Valve Society meeting in New York on April 12-14, 2018.

In his presentation, “Leaflet Restoration – a New Concept for Aortic Valve Restoration,” Dr Fontana will report on preclinical in-vitro and in-vivo studies to evaluate the safety and performance of Xeltis’ restorative aortic valve. The presentation is scheduled at 5.30pm ET on April 13, 2018.

Xeltis’ restorative technology enables the patient’s body to form a new valve with own tissue, potentially reducing the risk of complications leading to further interventions. Clinical tests on the safety and feasibility of pulmonary valves based on Xeltis’ restorative technology are under way in several pediatric centers across the United States. For more information: www.xplore2trial.com

Go back